Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice (original) (raw)
Adams GP, Weiner LM . Monoclonal antibody therapy of cancer. Nat Biotechnol 2005; 23: 1147–1157. ArticleCASPubMed Google Scholar
Hong CW, Zeng Q . Awaiting a new era of cancer immunotherapy. Cancer Res 2012; 72: 3715–3719. ArticleCASPubMed Google Scholar
Byrd JC, Kitada S, Flinn IW, Aron JL, Pearson M, Lucas D et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 2002; 99: 1038–1043. ArticleCASPubMed Google Scholar
Bannerji R, Kitada S, Flinn IW, Pearson M, Young D, Reed JC et al. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance. J Clin Oncol 2003; 21: 1466–1471. ArticleCASPubMed Google Scholar
Hubert P, Amigorena S . Antibody-dependent cell cytotoxicity in monoclonal antibody-mediated tumor immunotherapy. Oncoimmunology 2012; 1: 103–105. ArticlePubMedPubMed Central Google Scholar
Nimmerjahn F, Ravetch JV . Fcgamma receptors: old friends and new family members. Immunity 2006; 24: 19–28. ArticleCASPubMed Google Scholar
Winiarska M, Glodkowska-Mrowka E, Bil J, Golab J . Molecular mechanisms of the antitumor effects of anti-CD20 antibodies. Front Biosci (Landmark Ed) 2011; 16: 277–306. ArticleCAS Google Scholar
Dunkelberger JR, Song WC . Complement and its role in innate and adaptive immune responses. Cell Res 2010; 20: 34–50. ArticleCASPubMed Google Scholar
Zipfel PF, Skerka C . Complement regulators and inhibitory proteins. Nat Rev Immunol 2009; 9: 729–740. ArticleCASPubMed Google Scholar
Macor P, Tedesco F . Complement as effector system in cancer immunotherapy. Immunol Lett 2007; 111: 6–13. ArticleCASPubMed Google Scholar
Maher J, Adami AA . Antitumor immunity: easy as 1, 2, 3 with monoclonal bispecific trifunctional antibodies? Cancer Res 2013; 73: 5613–5617. ArticleCASPubMed Google Scholar
Baeuerle PA, Reinhardt C . Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 2009; 69: 4941–4944. ArticleCASPubMed Google Scholar
Brischwein K, Parr L, Pflanz S, Volkland J, Lumsden J, Klinger M et al. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. J Immunother 2007; 30: 798–807. ArticleCASPubMed Google Scholar
Haas C, Krinner E, Brischwein K, Hoffmann P, Lutterbuse R, Schlereth B et al. Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. Immunobiology 2009; 214: 441–453. ArticleCASPubMed Google Scholar
Baeuerle PA, Kufer P, Bargou R . BiTE: Teaching antibodies to engage T-cells for cancer therapy. Curr Opin Mol Ther 2009; 11: 22–30. CASPubMed Google Scholar
Klinger M, Brandl C, Zugmaier G, Hijazi Y, Bargou RC, Topp MS et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 2012; 119: 6226–6233. ArticleCASPubMed Google Scholar
Maetzel D, Denzel S, Mack B, Canis M, Went P, Benk M et al. Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol 2009; 11: 162–171. ArticleCASPubMed Google Scholar
Blok VT, Daha MR, Tijsma O, Harris CL, Morgan BP, Fleuren GJ et al. A bispecific monoclonal antibody directed against both the membrane-bound complement regulator CD55 and the renal tumor-associated antigen G250 enhances C3 deposition and tumor cell lysis by complement. J Immunol 1998; 160: 3437–3443. CASPubMed Google Scholar
Gelderman KA, Blok VT, Fleuren GJ, Gorter A . The inhibitory effect of CD46, CD55, and CD59 on complement activation after immunotherapeutic treatment of cervical carcinoma cells with monoclonal antibodies or bispecific monoclonal antibodies. Lab Invest 2002; 82: 483–493. ArticleCASPubMed Google Scholar
Klepfish A, Gilles L, Ioannis K, Rachmilewitz EA, Schattner A . Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions & clinical results in refractory CLL. Ann NY Acad Sci 2009; 1173: 865–873. ArticleCASPubMed Google Scholar
Klepfish A, Rachmilewitz EA, Kotsianidis I, Patchenko P, Schattner A . Adding fresh frozen plasma to rituximab for the treatment of patients with refractory advanced CLL. QJM 2008; 101: 737–740. ArticleCASPubMed Google Scholar
Tedesco F, Bulla B, Fischetti F . Terminal complement complex: regulation of formation and pathophysiological function. In: Szebeni J ed The Complement System: Novel Rules in Health and Disease, pp 97–127 2004.
Garred P, Hetland G, Mollnes TE, Stoervold G . Synthesis of C3, C5, C6, C7, C8, and C9 by human fibroblasts. Scand J Immunol 1990; 32: 555–560. ArticleCASPubMed Google Scholar
Langeggen H, Pausa M, Johnson E, Casarsa C, Tedesco F . The endothelium is an extrahepatic site of synthesis of the seventh component of the complement system. Clin Exp Immunol 2000; 121: 69–76. ArticleCASPubMedPubMed Central Google Scholar
Langeggen H, Berge KE, Macor P, Fischetti F, Tedesco F, Hetland G et al. Detection of mRNA for the terminal complement components C5, C6, C8 and C9 in human umbilical vein endothelial cells in vitro. APMIS 2001; 109: 73–78. ArticleCASPubMed Google Scholar
Gelderman KA, Tomlinson S, Ross GD, Gorter A . Complement function in mAb-mediated cancer immunotherapy. Trends Immunol 2004; 25: 158–164. ArticleCASPubMed Google Scholar
Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M . Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 2003; 40: 109–123. ArticleCASPubMed Google Scholar
Ziller F, Macor P, Bulla R, Sblattero D, Marzari R, Tedesco F . Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59. Eur J Immunol 2005; 35: 2175–2183. ArticleCASPubMed Google Scholar
Macor P, Tripodo C, Zorzet S, Piovan E, Bossi F, Marzari R et al. In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res 2007; 67: 10556–10563. ArticleCASPubMed Google Scholar
Golay J, Manganini M, Facchinetti V, Gramigna R, Broady R, Borleri G et al. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. Haematologica 2003; 88: 1002–1012. CASPubMed Google Scholar
Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000; 95: 3900–3908. CASPubMed Google Scholar
Di Gaetano N, Cittera E, Nota R, Vecchi A, Grieco V, Scanziani E et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003; 171: 1581–1587. ArticleCASPubMed Google Scholar
Di Niro R, Ziller F, Florian F, Crovella S, Stebel M, Bestagno M et al. Construction of miniantibodies for the in vivo study of human autoimmune diseases in animal models. BMC Biotechnol 2007; 7: 46. ArticlePubMedPubMed Central Google Scholar
Fang J, Qian JJ, Yi S, Harding TC, Tu GH, VanRoey M et al. Stable antibody expression at therapeutic levels using the 2A peptide. Nat Biotechnol 2005; 23: 584–590. ArticleCASPubMed Google Scholar
Hanke T, Szawlowski P, Randall RE . Construction of solid matrix-antibody-antigen complexes containing simian immunodeficiency virus p27 using tag-specific monoclonal antibody and tag-linked antigen. J Gen Virol 1992; 73 (Pt 3): 653–660. ArticleCASPubMed Google Scholar
Boscolo S, Mion F, Licciulli M, Macor P, De Maso L, Brce M et al. Simple scale-up of recombinant antibody production using an UCOE containing vector. N Biotechnol 2012; 29: 477–484. ArticleCASPubMed Google Scholar
Macor P, Mezzanzanica D, Cossetti C, Alberti P, Figini M, Canevari S et al. Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma. Cancer Res 2006; 66: 3876–3883. ArticleCASPubMed Google Scholar
Mezzaroba N, Zorzet S, Secco E, Biffi S, Tripodo C, Calvaruso M et al. New potential therapeutic approach for the treatment of B-Cell malignancies using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles. PLoS One 2013; 8: e74216. ArticleCASPubMedPubMed Central Google Scholar
Biffi S, Garrovo C, Macor P, Tripodo C, Zorzet S, Secco E et al. In vivo biodistribution and lifetime analysis of cy5.5-conjugated rituximab in mice bearing lymphoid tumor xenograft using time-domain near-infrared optical imaging. Mol Imaging 2008; 7: 272–282. ArticleCASPubMed Google Scholar
Biffi S, Dal Monego S, Dullin C, Garrovo C, Bosnjak B, Licha K et al. Dendritic polyglycerolsulfate near infrared fluorescent (NIRF) dye conjugate for non-invasively monitoring of inflammation in an allergic asthma mouse model. PLoS One 2013; 8: e57150. ArticleCASPubMedPubMed Central Google Scholar
Ridgway JB, Presta LG, Carter P . 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 1996; 9: 617–621. ArticleCASPubMed Google Scholar
Reed CD, Rast H, Hu WG, Mah D, Nagata L, Masri SA . Expression of furin-linked Fab fragments against anthrax toxin in a single mammalian expression vector. Protein Expr Purif 2007; 54: 261–266. ArticleCASPubMed Google Scholar
Funakoshi S, Longo DL, Murphy WJ . Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas. J Immunother Emphasis Tumor Immunol 1996; 19: 93–101. ArticleCASPubMed Google Scholar
Cragg MS, Morgan SM, Chan HT, Morgan BP, Filatov AV, Johnson PW et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 2003; 101: 1045–1052. ArticleCASPubMed Google Scholar
Cragg MS, Glennie MJ . Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 2004; 103: 2738–2743. ArticleCASPubMed Google Scholar
Gunn L, Ding C, Liu M, Ma Y, Qi C, Cai Y et al. Opposing roles for complement component C5a in tumor progression and the tumor microenvironment. J Immunol 2012; 189: 2985–2994. ArticleCASPubMed Google Scholar
Dobrina A, Pausa M, Fischetti F, Bulla R, Vecile E, Ferrero E et al. Cytolytically inactive terminal complement complex causes transendothelial migration of polymorphonuclear leukocytes in vitro and in vivo. Blood 2002; 99: 185–192. ArticleCASPubMed Google Scholar
Markiewski MM, DeAngelis RA, Benencia F, Ricklin-Lichtsteiner SK, Koutoulaki A, Gerard C et al. Modulation of the antitumor immune response by complement. Nat Immunol 2008; 9: 1225–1235. ArticleCASPubMedPubMed Central Google Scholar